Development of a novel anti-invasive drug candidate with improved efficacy for liver cancer therapy
DIMINISH will develop an MMP14 small molecule drug candidate via a unique and selective targeting approach. HCC is an invasive and highly vascularised tumour type and the most common form of liver cancer. DIMINISH will develop and deliver a highly potent and selective MMP14 inhibitor that strongly impairs the invasion and formation of new blood vessels directly, thereby reducing tumour growth and metastasis with improved efficacy and less side effects compared to the current HCC therapy.
1 508 110.00€
Pharmaceutical Products / Drugs